Literature DB >> 15930260

Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy.

Catherine M Shachaf1, Dean W Felsher.   

Abstract

Upon MYC inactivation, tumors variously undergo proliferative arrest, cellular differentiation, and apoptosis and in some cases, apparently permanently revoking tumorigenesis. In liver tumor cells, we recently showed that MYC inactivation uncovers stem cell properties and triggers differentiation, but in this case, their neoplastic properties are restorable by MYC reactivation. Thus, whereas oncogene inactivation can push cancer to the brink of normalcy, some cells retain the latent capacity to turn cancerous again, arguing that they may exist in a state of tumor dormancy.

Entities:  

Mesh:

Year:  2005        PMID: 15930260     DOI: 10.1158/0008-5472.CAN-05-1172

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

Review 1.  MYC as a regulator of ribosome biogenesis and protein synthesis.

Authors:  Jan van Riggelen; Alper Yetil; Dean W Felsher
Journal:  Nat Rev Cancer       Date:  2010-04       Impact factor: 60.716

Review 2.  Tumor cell dormancy induced by p38SAPK and ER-stress signaling: an adaptive advantage for metastatic cells?

Authors:  Aparna C Ranganathan; Alejandro P Adam; Lin Zhang; Julio A Aguirre-Ghiso
Journal:  Cancer Biol Ther       Date:  2006-07-01       Impact factor: 4.742

Review 3.  An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.

Authors:  Stephanie C Casey; Yulin Li; Dean W Felsher
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

4.  [Expression of NUF2 in breast cancer and its clinical significance].

Authors:  Jingbo Sun; Jiawei Chen; Zhizhi Wang; Yunyao Deng; Lixin Liu; Xiaolong Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-05-30

Review 5.  Cancer cell dormancy in novel mouse models for reversible pancreatic cancer: a lingering challenge in the development of targeted therapies.

Authors:  Wan-Chi Lin; Nirakar Rajbhandari; Kay-Uwe Wagner
Journal:  Cancer Res       Date:  2014-03-26       Impact factor: 12.701

6.  Cancer cell-derived clusterin modulates the phosphatidylinositol 3'-kinase-Akt pathway through attenuation of insulin-like growth factor 1 during serum deprivation.

Authors:  Hakryul Jo; Yonghui Jia; Kulandayan K Subramanian; Hidenori Hattori; Hongbo R Luo
Journal:  Mol Cell Biol       Date:  2008-05-05       Impact factor: 4.272

Review 7.  SGF29 and Sry pathway in hepatocarcinogenesis.

Authors:  Nobuya Kurabe; Shigekazu Murakami; Fumio Tashiro
Journal:  World J Biol Chem       Date:  2015-08-26

8.  The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism.

Authors:  Carlos Sebastián; Bernadette M M Zwaans; Dafne M Silberman; Melissa Gymrek; Alon Goren; Lei Zhong; Oren Ram; Jessica Truelove; Alexander R Guimaraes; Debra Toiber; Claudia Cosentino; Joel K Greenson; Alasdair I MacDonald; Liane McGlynn; Fraser Maxwell; Joanne Edwards; Sofia Giacosa; Ernesto Guccione; Ralph Weissleder; Bradley E Bernstein; Aviv Regev; Paul G Shiels; David B Lombard; Raul Mostoslavsky
Journal:  Cell       Date:  2012-12-07       Impact factor: 41.582

Review 9.  MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Authors:  Seyed Esmaeil Ahmadi; Samira Rahimi; Bahman Zarandi; Rouzbeh Chegeni; Majid Safa
Journal:  J Hematol Oncol       Date:  2021-08-09       Impact factor: 17.388

10.  Myc-oncogene inactivating effect by proline rich polypeptide (PRP-1) in chondrosarcoma JJ012 cells.

Authors:  Karina Galoian; Sean Scully; Armen Galoyan
Journal:  Neurochem Res       Date:  2008-07-09       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.